Cash Flow from Financial Activities: The net amount of cash transactions used in funding activities.
Nasus Pharma Ltd. (NSRX) had Cash Flow from Financial Activities of $13.60M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Balance Sheet Financials | |
$12.31M |
|
$0.02M |
|
$0.14M |
|
$12.45M |
|
$1.40M |
|
-- |
|
$0.05M |
|
$1.45M |
|
$11.00M |
|
$11.00M |
|
$11.00M |
|
11.71M |
|
| Cash Flow Statement Financials | |
$-6.04M |
|
$-0.95M |
|
|
Cash Flow from Financial Activities |
$13.60M |
$1.29M |
|
$7.90M |
|
$6.61M |
|
$0.51M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|